Discover Inscopix's latest contract research services (CRO) designed for pharmaceutical and biotech companies. In this webinar, Dr. Jonathan Nassi showcases the cutting-edge capabilities of the Inscopix Discovery Lab, which combines advanced in vivo miniscope imaging with behavioral analysis.
This innovative approach supports preclinical pharmaceutical programs by offering a unique method to assess new compounds and analyze the effects of drugs on brain function during active behavior.
Dr. Nassi also introduces an antidepressant profiling and reference library, developed in collaboration with pharmaceutical partners, with a featured case study and resulting data presented during the session.
Dr. Benjamin Siemsen of Supernus Pharmaceuticals, Inc. unveil the newest findings from a project conducted through the Inscopix Discovery Lab, in a presentation titled, “NV-5138 screening through Inscopix neurobehavioral assay: Comparison with ketamine and rapastinel”.
In this part of the session, Dr. Siemsen explores the demand for faster onset times in antidepressant treatments and how it has driven improvements in efficacy, leading to a wave of innovations in the field.
Rapid-acting antidepressants (RAADs) are believed to activate neuroplasticity mechanisms in critical brain regions associated with depression, such as the prefrontal cortex (PFC). NV-5138, a Phase 2 drug candidate with potential RAAD effects, was recently evaluated using the Inscopix neurobehavioral assay. Compared to ketamine and rapastinel, NV-5138 demonstrated a distinct neurobehavioral signature, which is explored in depth during this webinar.
About the speakers
Dr. Jonathan Nassi, Senior Director, Translational Science, Inscopix
Dr. Benjamin Siemsen, Senior Manager, Preclinical Pharmacology, Supernus Pharmaceuticals, Inc.
Watch the full webinar now